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Abstract New polypeptide components have been isolated from
Dendroaspis angusticeps venom using chromatography. Two
polypeptides containing 59 and 57 amino acids, called ‘DaE1’
and ‘DaE2’ respectively, have been purified to homogeneity and
fully sequenced. Spectrometric analysis yielded masses of 6631.5
and 6389.0 Da, respectively. The polypeptides share 98 and 95%
identity, respectively, with trypsin inhibitor E (DpE) of
Dendroaspis polylepis polylepis. ‘DaE’ polypeptides inhibit
Kv1.1 channels with an IC50 value in the range of 300 nM.
They can be considered as new dendrotoxins, albeit with fairly
low affinity as compared to K-DTX. ‘DaE’ polypeptides do not
affect Kir2.1 channels. ß 2001 Federation of European Bio-
chemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
Mambas are snakes of the Elapidae family belonging to the
genus Dendroaspis. At present, only four species endemic to
Africa are known: Dendroaspis angusticeps (Eastern green
mamba), Dendroaspis polylepis polylepis (black mamba), Den-
droaspis viridis (Western green mamba) and Dendroaspis
jamesoni kaimosae (Jameson’s mamba). In 1979, it was found
that D. angusticeps venom contains components that can fa-
cilitate the release of acetylcholine from nerve endings [1].
Subsequently, a polypeptide (named dendrotoxin, DTX) was
isolated from the same venom and assumed to be responsible
for the facilitatory actions [2]. In 1988, four di¡erent polypep-
tides from the venom of D. angusticeps were identi¢ed, des-
ignated as K-, L-, Q- and N-DTX. The amino acid composition
of K-DTX indicated that it was identical to DTX [3]. Two
similar polypeptides, called toxin I and K, have also been
isolated from D. polylepis polylepis [4].
Dendrotoxins are potent and selective neurotoxins because
of the following observations: (i) intracerebroventricular
(i.c.v.) injection of nanograms dendrotoxin per gram body
weight in rats induces strong epileptiform convulsions [5],
(ii) autoradiography on rat brain slices shows that 125I-labeled
dendrotoxins bind speci¢cally and with high a⁄nity to di¡er-
ent regions of the brain [6,7], and (iii) voltage clamp experi-
ments provide evidence for a selective block of voltage-depen-
dent (e.g. Kv1.1-type) K channels [7^12]. In addition, the
functional site of K-DTX important for the binding to Kv1-
type K channels on rat brain synaptosomal membranes has
been elucidated and includes six major binding residues, all
located in the N-terminal region, with Lys5 and Leu9 being
the most important [13]. From a structural point of view,
dendrotoxins are homologous to Kunitz serine protease inhib-
itors (e.g. BPTI), although dendrotoxins are weak inhibitors
of trypsin on the one hand, and, on the other hand, the
protease inhibitors do not block K channels [14,15].
While dendrotoxins are beyond doubt the most studied
polypeptides from mamba venom thus far, a variety of other
polypeptides (6^8 kDa) also exists. In a very recent review, an
attempt was made to classify all the known polypeptides from
mamba venoms in distinct structural groups [16]. The ¢rst
group is composed of three kinds of polypeptides: ‘true’ den-
drotoxins, protease inhibitors, with weaker activity on K
channels, and calcicludines, blockers of high-voltage activated
Ca2 channels. The second group contains short and long
K-neurotoxins, muscarinic toxins, anticholinesterases, ‘angus-
ticeps-type’ polypeptides (with low toxicity and unknown
properties) and calciseptines (speci¢c L-type Ca2 channel
blockers). In a third group are classi¢ed polypeptides of mis-
cellaneous structures, sometimes with unknown function
(e.g. dendroaspis natriuretic peptide (DNP), short neuro-
toxins-like (mambin and homologous structures), long poly-
peptides (DpA) and ribonucleases (DaN3)).
Given that mamba venom contains a myriad of bioactive
polypeptides in the range of 6000^8000 Da, the objective of
this work was to discover new Kv- and Kir-type channel-spe-
ci¢c toxins. Here we report the puri¢cation of two new poly-
peptide components from D. angusticeps venom. These two
polypeptides contain 59 and 57 amino acids, are called ‘DaE1’
and ‘DaE2’, respectively, have been sequenced and found to
share 98 and 95% identity, respectively, with trypsin inhibitor
E (DpE) of D. polylepis polylepis venom puri¢ed in 1978 [17].
Although less potent than K-DTX, ‘DaE’ polypeptides inhibit
Kv1.1 channels with an IC50 value in the range of 300 nM. In
contrast, they do not a¡ect Kir2.1 channels.
2. Materials and methods
2.1. Venom puri¢cation
Venom of D. angusticeps was purchased from Sigma (USA); 50 mg
was dissolved in 100 mM ammonium acetate, pH 7 (Merck, Ger-
many). After vortexing, the sample was clari¢ed by centrifugation at
14 000 rpm for 15 min and its supernatant was then applied onto a
Superdex 30 prep grade HiLoad 16/60 FPLC column (Pharmacia
LKB Biotech, Sweden) equilibrated with 100 mM ammonium acetate,
pH 7. The material was eluted with the same bu¡er at a £ow rate of
0.2 ml/min. Absorbance of the eluate was monitored at 280 nm and
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4 ml fractions were collected automatically. The fraction of interest
was recovered, lyophilized and applied on a Mono S HR 5/5 cation
exchange FPLC column (Pharmacia, Sweden) equilibrated with 50
mM phosphate bu¡er, pH 6.8. Separation was performed using a
linear gradient of 0^100% 1 M NaCl (supplemented with 50 mM
phosphate bu¡er, pH 6.8). The £ow rate was 1 ml/min and the ab-
sorbance was measured at 214 nm. Desalting of the material was
performed with a PepRPC HR 5/5 C2/C18 reversed phase FPLC col-
umn (Pharmacia, Sweden) equilibrated with 0.1% tri£uoroacetic acid
(TFA) in distilled water. Separation was performed by using a linear
gradient of 0^60% acetonitrile (supplemented with 0.1% TFA) for
40 min. The £ow rate was 0.5 ml/min and the absorbance was mea-
sured at 214 nm. Fractions containing the material of interest were
recovered, dried (Speed Vac Plus, Savant, USA), and applied to a
208TP5415 C8 reversed phase HPLC column (Vydac, USA) using
the same reversed phase solutions as above. Separation was performed
by using a linear gradient of 0^30% acetonitrile (supplemented with
0.1% TFA) between 4 and 6 min, followed by a linear gradient of
30^40% between 6 and 15 min.
2.2. Mass and sequence determination
The masses of the two polypeptides were determined by electro-
spray mass spectrometry which was performed on a Bio-Q quadru-
pole mass spectrometer equipped with an electrospray ionization
source (Micromass, Altrincham, UK). 20 Wl of sample solution, di-
luted in 50% acetonitrile in 0.5% formic acid, were injected manually
in the loop of the Rheodyne injector and pumped to the source at 6 Wl
per min. The solvent was delivered by a 140 A Solvent Delivery
System (Applied Biosystems, Foster City, CA, USA). Scans of 12 s
over the mass range of 400^1600 AMU were collected over 2 min.
Calibration of the instrument was performed with 50 pmol of horse
myoglobin (Sigma, USA). Mass determination of the internal peptides
was performed by the technique of matrix-assisted laser desorption
ionization mass spectrometry (MALDI-TOF-MS) carried out on a
TofSpec SE time-of-£ight instrument using a Nitrogen laser (337
nm) (Micromass, Wythenshawe, UK). Scans were accumulated over
20^70 laser shots, using a cyano hydroxycinnamic acid as matrix.
External calibration was realized using both angiotensin II and bovine
insulin (Sigma, USA). To avoid N-terminally blocked polypeptides
through cyclization of an N-terminal glutamine, the polypeptides
have been incubated with pyroglutamate aminopeptidase (Boehringer
Mannheim, Germany) subsequently for 18 h at 4‡C and 4 h at 25‡C in
a 100 mmol sodium phosphate bu¡er of pH 8, containing 10 mmol
EDTA, 5 mmol dithioerythritol and 5% glycerol, at an enzyme/sub-
strate ratio of 1/50. The cysteines in DaE1 and DaE2 have been
alkylated with 3-bromopropylamine (Sigma, USA) as described by
Jue and Hale [18]. Internal peptides of the alkylated DaE1 and
DaE2 have been obtained by enzymatic cleavage with endoproteinase
Glu-C (protease V8) (Boehringer Mannheim, Germany). The toxins
were incubated overnight at room temperature in 20 mM ammonium
bicarbonate of pH 8 at an enzyme/substrate ratio of 1/40. Separation
of the peptides resulting from the enzymatic cleavage was performed
on a Sephasil C18 sc 2.1/10 reversed phase column, installed on a
SMART chromatographic system (Pharmacia, Uppsala, Sweden) us-
ing gradient elution. Solvent A was 0.1% tri£uoracetic acid in water
and solvent B was 0.08% tri£uoracetic acid in 70% acetonitrile. Poly-
peptide puri¢cation after alkylation has been performed on a C18
YMC ODS-AQ, 2U100 mm column (YMC, New York, USA), in-
stalled on the SMART system, using the same solvents as for the
peptide separation. N-terminal and peptide sequence analyses were
performed on an automatic 476 A pulsed liquid sequenator equipped
with an on-line analyzer for PTH derivatives (Applied Biosystems,
Foster City, CA, USA).
2.3. Expression in oocytes
For in vitro transcription, plasmids were ¢rst linearized either with
NheI (for IRK1/pGEMHE2), or with PstI 3P to the 3P non-translated
L-globin sequence of RCK1/pGEMHE. Next the ‘Riboprobe Gemini
System’ was used (Promega, USA) with T7 RNA polymerase and a
cap analogue diguanosine triphosphate. Stage V^VI Xenopus laevis
oocytes were isolated by partial ovariectomy under anesthesia
(tricaine, 1 g/l). Anaesthetized animals were then kept on ice during
dissection. The oocytes were defolliculated by treatment with 2 mg/ml
collagenase (Boehringer Mannheim, Germany) in zero calcium ND-96
solution (see Section 2.5) for 45 min. Between 2 and 24 h after de-
folliculation, oocytes were pressure injected with 50 nl of 1^100 ng/Wl
mRNA. The oocytes were then incubated in ND-96 solution at 18‡C
for 1^4 days.
2.4. Electrophysiological recordings and analysis
Whole-cell currents from oocytes were recorded using the two-mi-
croelectrode voltage clamp technique (GeneClamp 500, Axon Instru-
Fig. 1. Puri¢cation of DaE1 and DaE2 from D. angusticeps.
A: Crude venom fractionated by FPLC gel ¢ltration as indicated in
Section 2. The labeled fraction (*) was recovered and lyophilized.
B: Second puri¢cation step using a Mono S HR 5/5 cation ex-
change column. The labeled fraction (*) was recovered and desalted
on a PepRPC HR 5/5 C2/C18 reversed phase column (C). The frac-
tion containing the material of interest was recovered, dried, and
applied to a 208TP5415 C8 reversed phase column for ¢nal puri¢ca-
tion (D).
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ments, USA). Resistances of voltage and current electrodes were kept
as low as possible (voltage electrode: 0.1^0.5 M6 ; current electrode:
0.1 M6) and were ¢lled with 3 M KCl. Current records were sampled
at 1 ms intervals and ¢ltered at 0.5 kHz, using a 4-pole low-pass
Bessel ¢lter. To eliminate the e¡ect of the voltage drop across the
bath grounding electrode, the bath potential was actively controlled,
as measured near the outside surface of the oocyte by means of a two-
electrode virtual-ground circuit (also called ‘bath clamp’). Leak cur-
rent amplitudes were only in the range of 1% of the amplitude of
time- and voltage-dependent currents. In non-injected or H2O-injected
oocytes (n = 20), endogenous currents observed in the tested voltage
range amounted only to approximately 1% of the amplitude of RCK1
and IRK1 currents. All experiments were performed at room temper-
ature (19^23‡C).
2.5. Solutions
The ND-96 solution contained (in mM): 96 NaCl, 2 KCl, 1.8
CaCl2, 1 MgCl2, 5 HEPES, pH 7.5, supplemented with 50 mg/ml
gentamicin sulfate (only for incubation).
3. Results and discussion
Crude venom from D. angusticeps was fractionated by
means of gel ¢ltration, ion exchange, and two reversed phase
steps as detailed in Section 2 and shown in Fig. 1. The masses
of two polypeptides of interest were determined by electro-
spray mass spectrometry. Spectrometric analysis of the two
polypeptides from D. angusticeps, which we named ‘DaE1’
and ‘DaE2’, yielded masses of 6631.5 and 6389.0 Da, respec-
tively.
To avoid the presence of N-terminally blocked polypeptides
through cyclization of the N-terminal glutamine (dendrotox-
ins indeed often appear N-terminally blocked), the two poly-
peptides have been incubated with pyroglutamate aminopep-
tidase as detailed in Section 2. The cysteine residues present in
DaE1 and DaE2 have been alkylated with 3-bromopropyl-
amine according to Jue and Hale [18]. Enzymatic cleavage
with endoproteinase Glu-C (protease V8) of the aminopropy-
lated toxins DaE1 and DaE2 resulted in 10 peptide fragments
(Table 1). Mass spectrometric data of these peptides revealed
an interesting ¢nding: the di¡erence between the experimen-
tally measured masses of peptides E4a and E4b, E5a and E5b,
and E6a and E6b, respectively, invariably totaled 241.4 Da.
This mass equals the mass of an N-terminal di-peptide com-
posed of a Leu and Gln residue, which we have been able to
con¢rm during sequence analysis (see also further). Further-
more, all the mass spectrometric data for the 10 di¡erent pep-
tides con¢rm the calculated masses and respective sequence
positions in the toxin. For instance, peptide E1 corresponds
with the sequence stretch Lys52^Gly59, has an experimental
mass of 1007.2 Da and a calculated mass of 1006.1 Da. Pep-
tide E6a corresponds with sequence position Leu1^Gly38 (see
toxin DaE1), has an experimental mass of 4558.3 Da and a
calculated mass of 4557.1 Da. In contrast, peptide E6b corre-
sponds with sequence position Hys3^Gly38 (see toxin DaE2),
has an experimental mass of 4316.8 Da and a calculated mass
of 4315.8 Da.
N-terminal and peptide sequencing permitted unequivocal
assignment of 59 residues for DaE1 and 57 residues for DaE2
(Fig. 2). Both peptides contain six Cys residues and only di¡er
from each other N-terminally with respect to the presence or
absence of residues Leu^Gln in DaE1 and DaE2, respectively.
The measured molecular masses of the two peptides, 6631.5
and 6389.0 Da respectively, ¢t to the obtained amino acid
sequences. The di¡erences between the measured and the pre-
dicted masses only amount to 0.02% and 0.03% respectively
(predicted masses for DaE1 and DaE2 with the Cys residues
in the oxidized state: 6633 Da and 6391 Da respectively).
When the amino acid sequences of DaE1 and DaE2 were
compared with other known proteins, (Swiss Prot and BLAST
data bank searches), the following observations could be:
DaE1 and DaE2 clearly belong to the ¢rst ‘structural’ group
of mamba polypeptides composed of ‘true’ dendrotoxins, pro-
tease inhibitors and calcicludines. These polypeptides are ba-
sic, contain 57^60 residues in total of which there are six Cys
residues, and display a high degree of homology in their C-
termini (residues 39^54). DaE1 and DaE2 share 98 and 95%
identity, respectively, with DpE, which is trypsin inhibitor E
[17]. It is interesting to note that all the residues of DpE and
DaE1 are identical, except at position 55 (His in DpE vs. Arg
in DaE1). As compared with other toxins of this group, the
following degrees of identity were calculated for DaE1: 53%
with K-DTX [3], 63% with N-DTX [3,20], 61% with Q-DTX [3],
Fig. 2. Primary structure of DaE1 and DaE2. The complete amino acid sequences of DaE1 and DaE2 are given and compared with those of
similar dendrotoxins, after manual alignment of the Cys residues (black boxes). DaE1 and DaE2 contain 59 and 57 amino acids, respectively.
They share 98 and 95% identity, respectively, with DpE [17]. DpE and DaE1 are identical, except at position 55 (see single arrow). DaE1 and
DaE2 di¡er only in the ¢rst two N-terminal residues (see double arrow). White boxes indicate sequence identity. The total number of residues
for each polypeptide, varying between 57 and 60, is summarized on the right. Other abbreviations: K- and Q-DTX [3], N-DTX [3,20], DTX I
and K [4], Dv 14 (unpublished, cited in [15]), and DpB [19].
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Table 1
Mass spectrometric data for the peptides obtained after Glu-C (E) endoproteinase digestions of the aminopropylated toxins DaE1 and DaE2
Peptide MALDI experimental mass (MH) (Da) Calculated mass (Da) Sequence position
E1 1007.2 1006.1 K52^G59
E2 1454.8 1453.5 G39^E51
E3 2072.4 2071.2 L34^E51
E4 a 3941.0 3939.4 L1^Q33
E4 b 3699.7 3698.1 H3^Q33
E5 a 5994.4 5992.7 L1^E51
E5 b 5753.0 5751.4 H3^E51
E6 a 4558.3 4315.8 L1^G38
E6 b 4316.8 4557.1 H3^G38
E7 2053.8 2054.2 G39^R55
All peptides contain at least one modi¢ed cysteine. The mass of the aminopropylated cysteine is 57 Da higher than that of a normal cysteine.
These modi¢cations are also counted in the calculated mass data. The numbering used for the indication of the sequence position is that of the
DaE1 toxin (59 residues). N-terminal peptides derived from DaE1 are indicated as a, those obtained from DaE2 are indicated as b. The pep-
tides E1, E4 a and b, E6 a and b and E7 are the products of aspeci¢c cleavages.
Fig. 3. Electrophysiological characterization of DaE polypeptides. Macroscopic current recordings obtained with the two-microelectrode voltage
clamp technique on X. laevis oocytes. A: Currents through Kv1.1 (RCK1) channels evoked from a holding potential of 390 mV stepped to
test potentials ranging from 360 to +10 mV, with 10 mV increments, in control (a), in the presence of 500 nM DaE (b), and after wash out
(O). B: Current^voltage relationship for the experiment illustrated in A. Current amplitudes were measured at the end of each test pulse.
C: Remaining current (%) plotted as a function of the test potential in the presence of 500 nM DaE, yielding a horizontal line indicative for
the absence of voltage-dependent block. D: The presence of 500 nM DaE does not shift the steady-state action curve of Kv1.1
(V1=2 =316.0 þ 3.1 mV in control (n = 10) and 316.5 þ 4.2 mV in the presence of DaE (n = 6)). E: Currents through Kir2.1 (IRK1) channels
evoked from a holding potential of 0 mV stepped to test potentials ranging from 3140 to +60 mV, with 20 mV increments. 500 nM DaE is
without e¡ect. Recordings were in symmetrical K solutions.
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50% with DTX I [4], 60% with DTX K [4], 63% with Dv 14
(unpublished, cited in [15]), and 56% with DpB [19].
The biological e¡ect of DaE polypeptides is represented in
Fig. 3. Application of 500 nM DaE produced an inhibitory
e¡ect of approximately 60% on the outward current through
Kv1.1 channels, heterologously expressed in X. laevis oocytes.
The inhibition was voltage-independent, reversible, did not
a¡ect the steady-state activation curve, and was characterized
by an IC50 value of W300 nM (n = 6). Consequently, DaE
polypeptides can be considered as new dendrotoxins, although
they have fairly low a⁄nity as compared to K-DTX (IC50
value Kv1.1W1 nM) [12]. Our electrophysiological results
are in accordance with the weak a⁄nity as displayed by sim-
ilar peptides, DaO1 and DaP1, with apparent a⁄nities of only
20^25 nM for 125I-DTX I binding sites in rat brain mem-
branes (unpublished results, but recently reviewed in [16]).
The critical residues by which K-DTX binds to rat brain syn-
aptosomal membranes have been determined using a muta-
tional approach based on site-directed mutagenesis and chem-
ical synthesis [13]. Substitutions of Lys5 and Leu9 decrease
the a⁄nity of K-DTX more than 1000-fold, and substitutions
of Arg3, Arg4, Leu6 and Ile8 by 5- to 30-fold. Based on this,
the authors concluded that the functional side of K-DTX in-
cludes six major binding residues, all located in the N-terminal
region, with Lys5 and Leu9 being the most important. It is
interesting to note that DaE polypeptides lack Lys5, but share
Arg4 with K-DTX and Leu9 with all dendrotoxins (100%
conserved). This partial similarity may explain the low a⁄nity
of DaE polypeptides. A preliminary study of this type was
also reported for DTX K [21]. Mutant DTX K toxins with
residues substituted in the K-helix near the C-terminus (R52A
or R53A) yielded binding parameters similar to those of wild-
type and native DTX K. Residues located in the L-turn, how-
ever, reduced binding with the rank order of decrease being
K26AEW25AsK24A = K28A. Furthermore, substitutions
in the ‘310-helix’ located closely to the L-turn, produced equiv-
alent e¡ects (K3AsK6A). In view of these results and as can
be seen from Fig. 2, DTX K and DaE polypeptides share
residues Lys6 and Trp25. Another nice and recently published
paper describes the critical residues constituting the functional
interaction surfaces of N-DTX and its voltage-gated Shaker
channel receptor [22]. It was shown that N-DTX uses a trian-
gular patch formed by seven side-chains (Lys3, Tyr4, Lys6,
Leu7, Pro8, Arg10 and Lys26) to block the Shaker channel.
Again, DaE polypeptides share only some of these residues
with N-DTX, viz. Lys6, Leu7 and Pro8, explaining the rather
weak a⁄nity for Kv1-type channels.
Finally, we found that DaE polypeptides do not a¡ect in-
ward recti¢er K channels, such as Kir2.1 expressed in oo-
cytes, which is in accordance with the selectivity pro¢le of K-
DTX, but not of N-DTX [23].
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